Biotherapeutics announced that its abstract, titled “Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic ...

VET3-T12 is under clinical development by KaliVir Immunotherapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs for Sarcomas have a 77% phase transition success rate ...

VET3-T12 is under clinical development by KaliVir Immunotherapeutics and currently in Phase I for Uterine Cancer.

Kennedy Jr. and others, prompts us to examine the history of the vaccine movement, how we got here, and how we should now ...

Depending on when and where you were born, you might have a particular scar on your arm that everyone else around you also ...

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpox Japan Biotechno Pharma Co., Ltd. engaged as exclusive ...

Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high ...

Rifampicin prevents the assembly of DNA and proteins into mature virus particles. The block, which occurs at a stage in the formation of the viral envelope, can be rapidly reversed by removal of ...